Overview

Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether itacitinib is safe and effective in the treatment of systemic sclerosis in adults.
Phase:
Phase 2
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris